Clinical trials: Cervical Intraepithelial Neoplasia Grade 2 (CIN2)
HPV Infection, Cervical Cancer
Therapeutic Abstention and Surveillance of Intra-epithelial Histological Lesions of High Grade Cervical CIN2 (Cervical Intraepithelial Neoplasia Grade 2). SUIVICIN
This study proposes to describe and evaluate the rate of spontaneous regression of CIN2 at 2 year of follow up in women between 18 and 39 year old.
- Trial name
- SUIVICIN (NCT04057924)
- Testing
- abstention from CIN2 treatment and surveillance for at least 2 years
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Bordeaux
HPV Infections, Cervical Cancer Stage IIa
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05027776
- Testing
- 2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years
- Where
- China
- Volunteers
- 1,348 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Intraepithelial Neoplasia Grade 2/3
A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)
This study evaluates the efficacy and safety of the experimental drug, BLS-ILB-E710c, in patients with Cervical Intraepithelial Neoplasia 2/3 (CIN2/3).
- Trial name
- NCT03274206
- Testing
- BLS-ILB-E710c
- Where
- 14 sites in South Korea
- Volunteers
- 126 people
- Sponsor
- BioLeaders Corporation
CIN2/3 Recurrence
Prognostic Value of Human Papillomavirus (HPV) Detection in Cervical Intra-epithelial Neoplasia (CIN) Recurrence After Conization
CIN2/3 have been increased for many years and mainly concern women aged 25-29 years. They are subsequent to a persistent HPV infection and are classically treated by conization.
- Trial name
- SUIVICOL (NCT01543048)
- Testing
- Study Follow-Up
- Where
- 4 sites in France
- Volunteers
- 106 people
- Sponsor
- University Hospital, Bordeaux
Human Papilloma Virus, Cervical Cancer
The Selfie Study- Assessing Novel Markers for Cervical Cancer Screening From Self-collected Samples
Cervical cancer is primarily caused by Human Papillomaviruses (HPV). Testing for HPV in cervical samples is now an option for cervical cancer screening.
- Conditions
- Human Papilloma Virus, Cervical Cancer, CIN 2/3
- Trial name
- SELFIE (NCT04423679)
- Testing
- Evalyn Brush
- Where
- United States
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- George Washington University
HPV Infections, Cervical Cancer Stage IIa
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05371353
- Where
- 2 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Intraepithelial Neoplasia Grade 2/3, Cervical Lesion
Accurate Screening and Prevention of Cervical Lesions-- Development of Accurate Screening Methods for Cervical Lesions
The goal of this observational study is to compare the accuracy and sensitivity of High-throughput human papilloma virus(HPV) typing and integrated assays with routine screening protocols (Cobas HPV test combined with thinprep…
- Trial name
- NCT05851079
- Testing
- TCT test, Vaginoscopy, High throughput HPV typing and integration detection methods
- Where
- China
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
HIV Infections, HPV Infection
Assessment of the Effectiveness of TA Versus LEEP for Cervical Cancer Risk Reduction in WLHIV in Mozambique
Given that WLWH are more likely to develop persistent HPV infection and CC, effective screening and the management and treatment of pre-cancerous cervical abnormalities is critical to decrease the global burden of cervical…
- Conditions
- HIV Infections, HPV Infection, CIN 2/3
- Trial name
- NCT06326294
- Testing
- Thermal ablation, LOOP ELECTROSURGICAL EXCISION PROCEDURE
- Where
- Mozambique
- Volunteers
- 4,844 people
- Sponsor
- Instituto Nacional de Saúde, Mozambique
Cervical Cancer, High Grade Sil
Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.
Nearly 8 000 new cervical cancer cases are diagnosed in South Africa per year; many are still undiagnosed and about 50% of diagnosed cases succumb per year.
- Conditions
- Cervical Cancer, High Grade Sil, CIN2
- Trial name
- DiaVACCS (NCT02956031)
- Testing
- Screening, Colposcopy, LLETZ
- Where
- South Africa
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Pretoria
Cervical Cancer
p16 and Ki-67 Stainings and Natural Killer (NK) Cells in CIN-II Management
The objective of this study is to evaluate the outcome of cervical intraepithelial neoplasia grade 2 (CIN-II) patients followed up without treatment for 24 months according to p16 and ki-67 immunohistochemical staining and to the…
- Trial name
- NCT02522585
- Testing
- Conservative management
- Volunteers
- 100 people
- Sponsor
- Parc de Salut Mar
Cervical Cancer, Precancerous Condition
Fenretinide in Treating Patients With Cervical Neoplasia
RATIONALE: Chemoprevention uses drugs to try and prevent development of cancer. Fenretinide may be effective in treating cervical neoplasia and preventing cervical cancer.
- Trial name
- NCT00003075
- Testing
- Fenretinide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Intraepithelial Neoplasia Grade 2/3, Recurrence
The Adjuvant Effect of HPV Vaccination on Recurrence of Cervical Precancer or Carcinoma in Women Undergoing Conization
Assessment of the association between human papillomavirus vaccination (HPV) and recurrences of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in women undergoing conization.
- Trial name
- NCT06258564
- Testing
- vaccination against human papillomavirus infection (HPV vaccination)
- Where
- 2 sites in Czechia
- Volunteers
- 12,000 people
- Sponsor
- Charles University, Czech Republic
Cervical Intraepithelial Neoplasia Grade 2
Evaluation of the PreCursor-M+® in CIN2
The goal of this observational study is to to evaluate the accuracy and sensitivity of PreCursor-M+ on a post-aliquot of liquid-based cytology (LBC) cervical samples (biopsy) obtained by physicians in a group of women with…
- Trial name
- NCT06403618
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- European Institute of Oncology
Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II
HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
The primary goal of this phase I open label study is to determine the safety and tolerability of pNGVL4aCRTE6E7L2 DNA vaccine, as administered by intramuscular (IM) injection with TriGrid™ electroporation to both HIV- or HIV+…
- Conditions
- Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
- Trial name
- NCT04131413
- Testing
- pNGVL4aCRTE6E7L2
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins